Breaking News Instant updates and real-time market news.

PTCT

PTC Therapeutics

$36.61

1.59 (4.54%)

16:40
07/19/18
07/19
16:40
07/19/18
16:40

PTC Therapeutics trading resumes

PTCT PTC Therapeutics
$36.61

1.59 (4.54%)

06/20/18
LEHM
06/20/18
DOWNGRADE
Target $45
LEHM
Underweight
Ionis Pharmaceuticals downgraded to Underweight from Equal Weight at Barclays
Barclays analyst Gena Wang downgraded Ionis Pharmaceuticals (IONS) to Underweight and lowered her price target for the shares to $45 from $52 after PTC Therapeutics (PTCT) reported competing spinal muscular atrophy data. Wang this morning also upgraded PTC to Equal Weight from Underweight.
06/20/18
LEHM
06/20/18
NO CHANGE
LEHM
Barclays upgrades PTC to Equal Weight, downgrades Ionis to Underweight
Barclays analyst Gena Wang upgraded PTC Therapeutics (PTCT) to Equal Weight from Underweight while downgrading Ionis Pharmaceuticals (IONS) to Underweight from Equal Weight. The analyst raised her price target on the former to $40 from $26 and lowered her price target on the latter to $45 from $52. Following PTC's new data in spinal muscular atrophy data, the analyst believes its risdiplam has "disruptive potential" to Ionis and Biogen's (BIIB) Spinraza.
06/20/18
WBLR
06/20/18
NO CHANGE
WBLR
Outperform
PTC Therapeutics weakness on Sarepta data overblown, says William Blair
William Blair analyst Raju Prasad believes the weakness in shares of PTC Therapeutics (PTCT) following Sarepta's (SRPT) micro-dystrophin gene therapy data is overblown. In a best-case scenario, the micro-dystrophin gene therapy could be approved in late 2021/early 2022 in the United States and potentially 2022/2023 in Europe, Prasad tells investors in a research note. As such, the analyst believes PTC management's projected five-year annual growth of 15% for Translarna due to increasing penetration in existing countries and potential label expansion remains likely. He still views Translarna and Emflaza revenues through 2022 plus cash on hand worth at least $35 per share, with $12 to $20 per share upside coming from risdiplam's potential in spinal muscular atrophy. Prasad keeps an Outperform rating on PTC Therapeutics.
07/19/18
FBCO
07/19/18
INITIATION
Target $49
FBCO
Outperform
PTC Therapeutics initiated with an Outperform at Credit Suisse
Credit Suisse initiated PTC Therapeutics with an Outperform and $49 price target.

TODAY'S FREE FLY STORIES

A

Agilent

$62.57

-2.42 (-3.72%)

07:22
11/20/18
11/20
07:22
11/20/18
07:22
Recommendations
Agilent analyst commentary  »

Agilent reported…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

07:20
11/20/18
11/20
07:20
11/20/18
07:20
General news
Futures point to continued selloff »

Stock futures are…

LYB

LyondellBasell

$92.77

-2.63 (-2.76%)

07:20
11/20/18
11/20
07:20
11/20/18
07:20
Upgrade
LyondellBasell rating change  »

LyondellBasell upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ASND

Ascendis Pharma

$58.24

-1.08 (-1.82%)

07:19
11/20/18
11/20
07:19
11/20/18
07:19
Recommendations
Ascendis Pharma analyst commentary  »

JPMorgan remains positive…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

NLSN

Nielsen

$25.24

-0.14 (-0.55%)

07:19
11/20/18
11/20
07:19
11/20/18
07:19
Hot Stocks
Nielsen board continues with review of strategic alternatives »

The Board of Directors is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDGS

Medigus

$2.95

-0.09 (-2.96%)

07:18
11/20/18
11/20
07:18
11/20/18
07:18
Hot Stocks
Medigus to form new company for mini video cameras »

Medigus announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AB

AllianceBernstein

$29.28

-0.37 (-1.25%)

07:17
11/20/18
11/20
07:17
11/20/18
07:17
Hot Stocks
AllianceBernstein announces offer to acquire Autonomous Research »

AllianceBernstein and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NLSN

Nielsen

$25.24

-0.14 (-0.55%)

, IBM

IBM

$120.37

-1.23 (-1.01%)

07:16
11/20/18
11/20
07:16
11/20/18
07:16
Hot Stocks
Nielsen names David Kenny as CEO, effective December 3 »

The Board of Directors of…

NLSN

Nielsen

$25.24

-0.14 (-0.55%)

IBM

IBM

$120.37

-1.23 (-1.01%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Nov

  • 03

    Mar

GMDA

Gamida Cell

$9.50

-0.48 (-4.81%)

07:16
11/20/18
11/20
07:16
11/20/18
07:16
Initiation
Gamida Cell initiated  »

Gamida Cell initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Dec

CODI

Compass Diversified

$15.11

-0.11 (-0.72%)

07:15
11/20/18
11/20
07:15
11/20/18
07:15
Conference/Events
Compass Diversified management to meet with Roth Capital »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Nov

  • 27

    Nov

  • 28

    Nov

07:15
11/20/18
11/20
07:15
11/20/18
07:15
General news
FX Update: There have been mixed themes »

FX Update: There have…

AAPL

Apple

$185.80

-7.62 (-3.94%)

07:14
11/20/18
11/20
07:14
11/20/18
07:14
Recommendations
Apple analyst commentary  »

Apple price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

STML

Stemline

$10.61

-0.76 (-6.68%)

07:14
11/20/18
11/20
07:14
11/20/18
07:14
Hot Stocks
Stemline announces EMA grants accelerated assessment for Elzonris MAA »

Stemline announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Dec

  • 03

    Dec

  • 21

    Feb

NJR

New Jersey Resources

$50.16

0.39 (0.78%)

07:12
11/20/18
11/20
07:12
11/20/18
07:12
Earnings
New Jersey Resources sees FY19 NFE $1.95-$2.05 »

NJR expects its regulated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

BECN

Beacon Roofing

$27.74

0.12 (0.43%)

07:11
11/20/18
11/20
07:11
11/20/18
07:11
Recommendations
Beacon Roofing analyst commentary  »

Beacon Roofing price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

NJR

New Jersey Resources

$50.16

0.39 (0.78%)

07:10
11/20/18
11/20
07:10
11/20/18
07:10
Earnings
New Jersey Resources reports Q4 EPS (18c), consensus (44c) »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

BKI

Black Knight

$45.54

-4.23 (-8.50%)

07:09
11/20/18
11/20
07:09
11/20/18
07:09
Recommendations
Black Knight analyst commentary  »

Black Knight price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Dec

CELC

Celcuity

$24.00

-0.7 (-2.83%)

07:08
11/20/18
11/20
07:08
11/20/18
07:08
Initiation
Celcuity initiated  »

Celcuity initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APLS

Apellis

$14.38

-0.72 (-4.77%)

, BIIB

Biogen

$319.15

-4.86 (-1.50%)

07:08
11/20/18
11/20
07:08
11/20/18
07:08
Hot Stocks
Apellis appoints Adam Townsend as CCO »

Apellis (APLS) announced…

APLS

Apellis

$14.38

-0.72 (-4.77%)

BIIB

Biogen

$319.15

-4.86 (-1.50%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Dec

BBY

Best Buy

$62.19

-4.22 (-6.35%)

07:07
11/20/18
11/20
07:07
11/20/18
07:07
Earnings
Best Buy sees Q4 EPS $2.48-$2.58, consensus $2.58 »

Sees Q4 Enterprise…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 05

    Dec

CLBS

Caladrius

$4.70

-0.18 (-3.69%)

07:06
11/20/18
11/20
07:06
11/20/18
07:06
Initiation
Caladrius initiated  »

Caladrius assumed with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BBY

Best Buy

$62.19

-4.22 (-6.35%)

07:05
11/20/18
11/20
07:05
11/20/18
07:05
Earnings
Best Buy raises FY19 EPS view to $5.09-$5.19 from $4.95-$5.10 »

Consensus $5.11. Sees…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 05

    Dec

RNSDF

Renault

$0.00

(0.00%)

, NSANY

Nissan

$0.00

(0.00%)

07:05
11/20/18
11/20
07:05
11/20/18
07:05
Periodicals
Renault board to discuss interim replacement for Ghosn, Reuters reports »

The board of French…

RNSDF

Renault

$0.00

(0.00%)

NSANY

Nissan

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OASM

Oasmia

$4.30

-0.64 (-12.96%)

07:05
11/20/18
11/20
07:05
11/20/18
07:05
Hot Stocks
Oasmia announces notice of allowance for nanotech patent from USPTO »

Oasmia announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KSS

Kohl's

$70.75

-1.73 (-2.39%)

07:04
11/20/18
11/20
07:04
11/20/18
07:04
Earnings
Kohl's narrows FY18 EPS view to $4.35-$5.55 from $5.15-$5.55, consensus $5.51 »

Kohl's is raising…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.